+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Asthma Drugs Market by Product Type, Drug Class, Delivery Mode, Disease Type, End Users, Distribution Channel - Global Forecast 2026-2032- Product Image
Asthma Drugs Market by Product Type, Drug Class, Delivery Mode, Disease Type, End Users, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Asthma Drugs Market by Product Type, Drug Class, Delivery Mode, Disease Type, End Users, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5313699
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Asthma Drugs Market is projected to reach USD 27.31 Billion in 2026. It is expected to continue growing at a CAGR of 6.34%, reaching USD 39.62 Billion by 2032.

Asthma drugs remain central to respiratory care because asthma is one of the world’s most common chronic diseases. The World Health Organization reported that asthma affected about 262 million people in 2019 and caused approximately 455,000 deaths, with preventable morbidity concentrated where diagnosis, inhaled corticosteroids, and specialist care are inconsistent. This makes the asthma therapeutics market both a high-volume maintenance category and a precision-medicine growth segment.

The market spans inhaled corticosteroids, long-acting beta agonists, leukotriene receptor antagonists, long-acting muscarinic antagonists, short-acting relievers, fixed-dose inhaler combinations, and injectable biologics. Current clinical practice is increasingly aligned with Global Initiative for Asthma guidance that prioritizes inhaled corticosteroid-containing therapy and discourages reliance on short-acting bronchodilator-only treatment for adults and adolescents.

Growth is being shaped by rising respiratory disease awareness, air pollution exposure, aging populations, pediatric asthma management, biologic adoption for severe asthma, and the expansion of digital inhaler ecosystems. At the same time, pricing pressure, generic competition, inhaler sustainability requirements, and unequal access to essential asthma medicines are redefining commercial strategy.

Transformative Shifts in the Asthma Drugs Landscape

The asthma drugs landscape is shifting from symptom relief toward risk reduction, exacerbation prevention, and phenotype-guided care. Inhaled corticosteroid-based regimens remain the foundation of treatment, while combination inhalers and maintenance-and-reliever approaches are gaining clinical relevance because they reduce exacerbation risk compared with reliever-only patterns.

Severe asthma is undergoing the most visible transformation. Biologics targeting IgE, IL-5, IL-5 receptor, IL-4 receptor alpha, and TSLP have moved treatment beyond broad anti-inflammatory control toward biomarker-informed prescribing. Blood eosinophils, fractional exhaled nitric oxide, allergy status, oral corticosteroid dependence, and exacerbation history now influence therapy selection and payer authorization.

The competitive environment is also changing through device innovation, generic inhaler approvals, value-based contracting, and environmental policy. Regulators and health systems are scrutinizing hydrofluorocarbon-based metered dose inhalers, while dry powder inhalers, soft mist inhalers, propellant reformulation, and recycling programs are becoming strategic differentiators.

Cumulative Impact of Artificial Intelligence on Asthma Therapeutics

Artificial intelligence is becoming a practical accelerator across asthma drug discovery, clinical development, diagnosis, adherence, and post-market surveillance. In research, AI models help identify inflammatory pathways, stratify patients by phenotype, and support target validation for severe asthma and overlapping respiratory conditions.

In clinical development, machine learning can improve trial design by identifying high-risk patients, predicting exacerbation patterns, and reducing screen failures in biomarker-defined studies. Real-world evidence platforms using electronic health records, claims data, spirometry, wearable data, and smart inhaler use can help evaluate medication persistence, inhaler technique, and health-system outcomes.

Commercially, AI-enabled patient support tools can detect poor adherence, forecast refill gaps, and personalize education. The most credible use cases will require transparent algorithms, privacy protection, clinically validated endpoints, and careful mitigation of bias, particularly because asthma outcomes are strongly influenced by housing, pollution exposure, income, and access to care.

Key Regional Insights for Asthma Drugs

Asia-Pacific is a high-growth region for asthma drugs because of large patient populations, rapid urbanization, industrial air pollution, tobacco exposure, and expanding healthcare coverage. China, India, Japan, South Korea, and Australia represent distinct demand pools, ranging from high-volume inhaled corticosteroid and combination therapy use to advanced biologic uptake in specialist centers.

North America remains a leading region for branded biologics, advanced inhaler combinations, payer-managed formularies, and digital respiratory care. The United States has a large diagnosed asthma population and strong specialty prescribing infrastructure, while Canada’s public-private reimbursement environment supports evidence-based access but requires careful health technology assessment alignment.

Latin America shows growing demand for affordable controller medicines, especially in Brazil and Mexico, where urban pollution and healthcare access gaps shape asthma outcomes. Europe is characterized by robust clinical guidelines, regulatory maturity, biosimilar and generic competition, and heightened attention to low-carbon inhaler policy. The Middle East faces asthma triggers linked to dust, heat, smoking, and urban development, while Africa’s market is constrained by underdiagnosis, limited spirometry access, and inconsistent availability of inhaled corticosteroids, creating significant public health opportunity.

Key Group Insights for Asthma Drugs

ASEAN markets are expanding as urban air quality concerns, pediatric respiratory disease awareness, and broader insurance coverage support demand for inhaled maintenance therapy. However, pricing sensitivity and fragmented access make affordable inhaled corticosteroids and fixed-dose combinations critical to market penetration.

The GCC represents a premium respiratory care environment with strong hospital infrastructure, high specialist access in major cities, and demand for severe asthma biologics. Environmental triggers, including dust storms and high particulate exposure, reinforce the need for prevention-focused asthma management and adherence support.

The European Union influences global asthma drug strategy through centralized regulatory pathways, pharmacovigilance standards, environmental policy, and health technology assessment. BRICS countries combine large patient volumes with local manufacturing ambitions, making cost-effective inhalers, generics, and selective biologic access essential. G7 markets drive innovation adoption through advanced reimbursement systems and real-world evidence expectations, while NATO-aligned healthcare systems emphasize supply continuity, medicine security, and resilient procurement for essential respiratory drugs.

Key Country Insights for Asthma Drugs

The United States is a core market for asthma biologics, combination inhalers, and patient support programs, supported by specialist networks and large payer databases. Canada emphasizes guideline-based access and cost-effectiveness, while Mexico and Brazil offer substantial volume opportunities for affordable controllers and improved diagnosis in primary care.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature respiratory guidelines with payer scrutiny and growing environmental pressure on inhaler selection. Germany and France are important for evidence-driven reimbursement, the United Kingdom is influential in severe asthma pathways and low-carbon prescribing, and Italy and Spain remain significant markets for fixed-dose inhaled therapies. Russia presents demand for essential asthma medicines but faces access and supply-chain complexity.

Across Asia-Pacific, China and India are high-volume markets where urban pollution, expanding insurance coverage, and local manufacturing shape growth. Japan and South Korea show strong uptake of innovative therapies and digital health integration, while Australia has advanced respiratory guidelines and high awareness of preventable exacerbations. Together, these countries define the competitive balance between affordability, innovation, and outcomes-based care.

Actionable Recommendations for Asthma Drug Industry Leaders

Industry leaders should prioritize broad access to inhaled corticosteroid-containing therapy because preventable exacerbations remain a major clinical and economic burden. Portfolio strategies should balance affordable generics, differentiated combination inhalers, and biologics for severe asthma to capture both high-volume and high-value segments.

Companies should strengthen biomarker-enabled pathways for biologics by investing in evidence around eosinophils, FeNO, allergy status, exacerbation reduction, oral corticosteroid sparing, and quality-of-life improvement. Payer engagement must be supported by real-world outcomes, adherence data, and clear patient selection criteria.

Leaders should also prepare for environmental requirements by advancing low-carbon inhaler options, propellant transitions, device lifecycle programs, and patient education that preserves clinical effectiveness. Digital inhaler partnerships, AI-enabled adherence tools, and integrated respiratory platforms can improve differentiation when backed by validated outcomes and privacy-by-design systems.

Research Methodology

This executive summary is developed using a structured secondary research methodology supported by validated public health, regulatory, clinical, and market intelligence sources. Core inputs include World Health Organization disease burden data, Global Initiative for Asthma treatment strategy updates, national health agency statistics, regulatory approval trends, peer-reviewed respiratory medicine literature, and evidence from real-world asthma management programs.

The analysis triangulates disease prevalence, treatment guidelines, product class dynamics, reimbursement factors, regional access patterns, and emerging technology signals. Qualitative assessment is applied to competitive positioning, biologic adoption, inhaler-device trends, sustainability policy, and AI-enabled care models.

All insights are reviewed for consistency with verified industry evidence and framed for executive decision-making. The methodology avoids unsupported market-size claims and emphasizes trends that are observable through clinical guidelines, regulatory activity, payer behavior, epidemiology, and healthcare infrastructure development.

Conclusion

The asthma drugs market is moving toward a more integrated model of care that combines controller-first treatment, precision biologics, digital adherence, and sustainability-oriented inhaler innovation. Demand remains supported by the large global asthma burden and the continued need to reduce exacerbations, emergency visits, and avoidable deaths.

Competitive success will depend on delivering measurable outcomes across diverse healthcare systems. Organizations that expand access to essential controller medicines, build differentiated severe asthma portfolios, validate AI-enabled tools, and align with environmental policy will be best positioned for long-term growth.

Asthma therapeutics will continue to evolve from a product-centered market into an outcomes-centered ecosystem, where clinical evidence, affordability, device usability, and patient engagement determine leadership.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Asthma Drugs Market, by Product Type
7.1. Inhalers
7.2. Nebulizers
7.2.1. Jet Nebulizers
7.2.2. Ultrasonic Nebulizers
7.2.3. Mesh Nebulizers
7.3. Oral drugs
7.3.1. Tablets
7.3.2. Capsules
7.3.3. Syrups
7.4. Injectable
8. Asthma Drugs Market, by Drug Class
8.1. Albuterol
8.2. Beta Agonists
8.3. Brochodilators
8.4. Corticosteroids
8.5. Leukotriene Modifiers
9. Asthma Drugs Market, by Delivery Mode
9.1. Inhalable
9.2. Oral
10. Asthma Drugs Market, by Disease Type
10.1. Allergic Asthma
10.2. Non-allergic Asthma
11. Asthma Drugs Market, by End Users
11.1. Ambulatory Surgery Centers
11.2. Home Care Settings
11.3. Hospitals & Clinics
12. Asthma Drugs Market, by Distribution Channel
12.1. Online
12.2. Offline
13. Asia-Pacific Asthma Drugs Market
14. North America Asthma Drugs Market
15. Latin America Asthma Drugs Market
16. Europe Asthma Drugs Market
17. Middle East Asthma Drugs Market
18. Africa Asthma Drugs Market
19. ASEAN Asthma Drugs Market
20. GCC Asthma Drugs Market
21. European Union Asthma Drugs Market
22. BRICS Asthma Drugs Market
23. G7 Asthma Drugs Market
24. NATO Asthma Drugs Market
25. United States Asthma Drugs Market
26. Germany Asthma Drugs Market
27. China Asthma Drugs Market
28. United Kingdom Asthma Drugs Market
29. India Asthma Drugs Market
30. Japan Asthma Drugs Market
31. Russia Asthma Drugs Market
32. Brazil Asthma Drugs Market
33. Canada Asthma Drugs Market
34. Italy Asthma Drugs Market
35. Mexico Asthma Drugs Market
36. France Asthma Drugs Market
37. Spain Asthma Drugs Market
38. Australia Asthma Drugs Market
39. South Korea Asthma Drugs Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. ALK-Abelló A/S
41.2. Amphastar Pharmaceuticals, Inc.
41.3. AstraZeneca PLC
41.4. Bayer AG
41.5. Boehringer Ingelheim International GmbH
41.6. CHIESI Farmaceutici S.p.A.
41.7. Cipla Limited
41.8. Dr.Reddy’s Laboratories Ltd
41.9. F. Hoffmann-La Roche Ltd.
41.10. GlaxoSmithKline PLC
41.11. Hetero Labs Limited
41.12. Lallemand Inc.
41.13. Merck KGaA
41.14. Mundipharma International Limited
41.15. NIOX Group PLC
41.16. Novartis AG
41.17. Novo Holdings
41.18. OPKO Health, Inc.
41.19. Pfizer Inc.
41.20. Sanner GmbH
41.21. Sanofi S.A.
41.22. Sunovion Pharmaceuticals Inc.
41.23. Teva Pharmaceutical Industries Ltd.
41.24. Verona Pharma PLC
41.25. Viatris, Inc.
List of Figures
FIGURE 1. GLOBAL ASTHMA DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ASTHMA DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ASTHMA DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ASTHMA DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ASTHMA DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL ASTHMA DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 25. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. EUROPE ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. EUROPE ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. AFRICA ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. AFRICA ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. ASEAN ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. ASEAN ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. GCC ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. GCC ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. G7 ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. G7 ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. NATO ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. NATO ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. UNITED STATES ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. GERMANY ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. CHINA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. INDIA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. JAPAN ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. RUSSIA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. BRAZIL ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. CANADA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. ITALY ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. MEXICO ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. FRANCE ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SPAIN ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. AUSTRALIA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ASTHMA DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ASTHMA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ASTHMA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ASTHMA DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL ASTHMA DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL INHALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL INHALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL INHALERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NEBULIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NEBULIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NEBULIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL JET NEBULIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL JET NEBULIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL JET NEBULIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ULTRASONIC NEBULIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ULTRASONIC NEBULIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ULTRASONIC NEBULIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MESH NEBULIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MESH NEBULIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MESH NEBULIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ORAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ORAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ORAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL SYRUPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL SYRUPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SYRUPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ALBUTEROL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ALBUTEROL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ALBUTEROL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL BETA AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL BETA AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL BETA AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL BROCHODILATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL BROCHODILATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL BROCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL LEUKOTRIENE MODIFIERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL LEUKOTRIENE MODIFIERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL LEUKOTRIENE MODIFIERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL INHALABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL INHALABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL INHALABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL NON-ALLERGIC ASTHMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL NON-ALLERGIC ASTHMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL NON-ALLERGIC ASTHMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL AMBULATORY SURGERY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL AMBULATORY SURGERY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL AMBULATORY SURGERY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. EUROPE ASTHMA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. EUROPE ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 115. EUROPE ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 116. EUROPE ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 117. EUROPE ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 118. EUROPE ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 119. EUROPE ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 120. EUROPE ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 121. EUROPE ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 124. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. AFRICA ASTHMA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. AFRICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 133. AFRICA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 134. AFRICA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 135. AFRICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 136. AFRICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 137. AFRICA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 138. AFRICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 139. AFRICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 140. ASEAN ASTHMA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 141. ASEAN ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 142. ASEAN ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 143. ASEAN ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 144. ASEAN ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 145. ASEAN ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 146. ASEAN ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 147. ASEAN ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 148. ASEAN ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 149. GCC ASTHMA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 150. GCC ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 151. GCC ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 152. GCC ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 153. GCC ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 154. GCC ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 155. GCC ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 156. GCC ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 157. GCC ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. BRICS ASTHMA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 168. BRICS ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 169. BRICS ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 170. BRICS ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 171. BRICS ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 172. BRICS ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 173. BRICS ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 174. BRICS ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 175. BRICS ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 176. G7 ASTHMA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 177. G7 ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 178. G7 ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 179. G7 ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 180. G7 ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 181. G7 ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 182. G7 ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 183. G7 ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 184. G7 ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 185. NATO ASTHMA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 186. NATO ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 187. NATO ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 188. NATO ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 189. NATO ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 190. NATO ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 191. NATO ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 192. NATO ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 193. NATO ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. UNITED STATES ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 195. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 196. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 197. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 198. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 199. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 200. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 201. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 202. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 203. GERMANY ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 204. GERMANY ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 205. GERMANY ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 206. GERMANY ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 207. GERMANY ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 208. GERMANY ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 209. GERMANY ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 210. GERMANY ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 211. GERMANY ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 212. CHINA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 213. CHINA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 214. CHINA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 215. CHINA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 216. CHINA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 217. CHINA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 218. CHINA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 219. CHINA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 220. CHINA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 221. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 222. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 223. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 224. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 225. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 226. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 227. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 228. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 229. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 230. INDIA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 231. INDIA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 232. INDIA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 233. INDIA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 234. INDIA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 235. INDIA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 236. INDIA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 237. INDIA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 238. INDIA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 239. JAPAN ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 240. JAPAN ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 241. JAPAN ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 242. JAPAN ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 243. JAPAN ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 244. JAPAN ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 245. JAPAN ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 246. JAPAN ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 247. JAPAN ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 248. RUSSIA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 249. RUSSIA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 250. RUSSIA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 251. RUSSIA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 252. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 253. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 254. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 255. RUSSIA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 256. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 257. BRAZIL ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 258. BRAZIL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 259. BRAZIL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 260. BRAZIL ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 261. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 262. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 263. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 264. BRAZIL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 265. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 266. CANADA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 267. CANADA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 268. CANADA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 269. CANADA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 270. CANADA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 271. CANADA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 272. CANADA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 273. CANADA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 274. CANADA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 275. ITALY ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 276. ITALY ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 277. ITALY ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 278. ITALY ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 279. ITALY ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 280. ITALY ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 281. ITALY ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 282. ITALY ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 283. ITALY ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 284. MEXICO ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 285. MEXICO ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 286. MEXICO ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 287. MEXICO ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 288. MEXICO ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 289. MEXICO ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 290. MEXICO ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 291. MEXICO ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 292. MEXICO ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 293. FRANCE ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 294. FRANCE ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 295. FRANCE ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 296. FRANCE ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 297. FRANCE ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 298. FRANCE ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 299. FRANCE ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 300. FRANCE ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 301. FRANCE ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 302. SPAIN ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 303. SPAIN ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 304. SPAIN ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 305. SPAIN ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 306. SPAIN ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 307. SPAIN ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 308. SPAIN ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 309. SPAIN ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 310. SPAIN ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 311. AUSTRALIA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 312. AUSTRALIA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 313. AUSTRALIA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 314. AUSTRALIA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 315. AUSTRALIA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 316. AUSTRALIA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 317. AUSTRALIA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 318. AUSTRALIA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 319. AUSTRALIA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 320. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 321. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 322. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
TABLE 323. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
TABLE 324. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 325. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 326. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 327. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 328. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Asthma Drugs market report include:
  • ALK-Abelló A/S
  • Amphastar Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici S.p.A.
  • Cipla Limited
  • Dr.Reddy’s Laboratories Ltd
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hetero Labs Limited
  • Lallemand Inc.
  • Merck KGaA
  • Mundipharma International Limited
  • NIOX Group PLC
  • Novartis AG
  • Novo Holdings
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Sanner GmbH
  • Sanofi S.A.
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Verona Pharma PLC
  • Viatris, Inc.

Table Information

Report AttributeDetails
No. of Pages187
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 27.31 Billion
Forecasted Market Value ( USD ) by 2032 $ 39.62 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Asthma Drugs - Global Strategic Business Report - Product Image

Asthma Drugs - Global Strategic Business Report

  • Report
  • 177 Pages
  • Global
From
Asthma Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Asthma Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Asthma Drugs Market by Mode of Administration; Medication; Application; Organization Type; Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035 - Product Image

Asthma Drugs Market by Mode of Administration; Medication; Application; Organization Type; Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035

  • Report
  • 260 Pages
  • Global
From
Asthma Drugs Market Report 2026 - Product Image

Asthma Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Eosinophilic Asthma Drug Pipeline Analysis Report 2025 - Product Image

Eosinophilic Asthma Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From

About the Asthma Treatment Market

The Asthma Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of medications used to treat asthma. Asthma is a chronic respiratory condition that affects the airways, causing difficulty breathing, coughing, and wheezing. Asthma drugs are designed to reduce inflammation in the airways, making it easier for patients to breathe. These drugs can be taken orally, inhaled, or injected, depending on the severity of the condition. Common asthma drugs include corticosteroids, bronchodilators, and leukotriene modifiers. Some of the major companies in the Asthma Drugs market include GlaxoSmithKline, Merck & Co., Novartis, Pfizer, and Sanofi. These companies are involved in the research, development, and marketing of asthma drugs, as well as the production of generic versions of existing drugs. They also provide support services to patients, such as educational materials and access to specialists. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.